Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Auto/Allo and Tandem Auto HCT for MM Compared
Biol Blood Marrow Transplant; ePub 2017 Oct 25; Htut, et al
Patients with relapsed multiple myeloma who undergo autologous-allogenenic (auto/allo) hematopoietic cell transplantation (HCT) tend to survive longer than those who receive tandem auto HCT, according to a study involving 822 individuals. Investigators looked at post relapse survival in participants who underwent either auto/allo (n=264) or tandem auto (n=558) HCT between 2000 and 2010. Among the results:
- At a median follow up of 8.5 years, 72% of patients who received tandem auto HCT relapsed; vs 67% of those who underwent auto/allo HCT.
- 26% of patients who received tandem auto HCT relapsed <6 months from their second HCT, vs 46% of those who underwent auto/allo HCT.
- 6-year post-relapse survival rates were 35% and 44%, respectively.
- Death due to multiple myeloma occurred in 83% and 69%, respectively.
- Death rates in the first year after relapse were similar in both groups.
- After 1 year, overall survival was superior in those receiving auto/allo HCT.
Htut M, D'Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation (HCT) versus tandem autologous transplantation for multiple myeloma—comparison of long term post relapse survival. [Published online ahead of print October 25, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.10.024.